The Androgen Receptor pipeline drugs market research report outlays comprehensive information on the Androgen Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Androgen Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Hormonal Disorders, Dermatology, and Genito Urinary System which include the indications Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Male Hypogonadism, Testicular (Primary) Hypogonadism, Androgenic Alopecia, Acne Vulgaris, Male Contraception, and Male Infertility. It also reviews key players involved in Androgen Receptor targeted therapeutics development with respective active and dormant or discontinued products.
The Androgen Receptor pipeline targets constitutes close to 117 molecules. Out of which, approximately 100 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 4, 8, 25, 11, 35, and 15 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical, and Discovery comprises 2, 1, 12, and 2 molecule.
Androgen Receptor overview
The androgen receptor (AR), also known as NR3C4 (nuclear receptor subfamily 3, group C, member 4), is a protein that functions as a transcription factor. It is activated by binding the androgenic hormones testosterone and dihydrotestosterone (DHT). The receptors are present in many of the body’s tissues, where they bind to androgens. The resulting androgen-receptor complex then binds to DNA and regulates the activity of androgen-responsive genes.
For a complete picture of Androgen Receptor’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
